Early Data On Cimzia® Shows Promise In Crohn’s Patients Without Infliximab
Mar 14th 2008Drug InformationCrohn
Datafrom the WELCOME trial presented at the third congress of the EuropeanCrohn’s and Colitis Organisation (ECCO) show that, at the six weekmark, Cimzia® (certolizumab pegol) is effective in Crohn’s patientsshowing intolerance or no response to infliximab. Crohn’sDisease (CD) is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
